The upregulation of PLOD1, PLOD2, and PLOD3 in ccRCC tissues, their association with poor clinical outcomes, and their roles in ECM remodeling and immune modulation highlight their potential as diagnostic biomarkers and therapeutic targets. Here, PLOD3 is linked to nonpapillary renal cell carcinoma.